Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Glooko, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Glooko, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6. MindMaze Therapeutics appears in 1 tracked Biotech story from March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MindMaze Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
MindMaze Therapeutics has appointed digital health veteran Zach Henderson as its new Chief Executive Officer to lead the company's transition into a global commercial-stage entity. Henderson brings extensive experience from Glooko and Welldoc to accelerate the adoption of MindMaze’s neuro-rehabilitation platform.
MindMaze Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
